Pfizer has been leaning on recently acquired products to offset a looming patent cliff.

Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.

Pfizer (NYSE:PFE) is preparing multiple presentations for the upcoming ASCO conference that spotlight new data across its ...

Q1 earnings May 4: analyst EPS/revenue estimates, 2026 guidance focus, oncology & obesity pipeline catalysts, and cost cuts.

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

Track Pfizer share price today on NSE/BSE with real-time updates. Check stock performance, fundamentals, market cap, ...

Despite discontinuing an early-stage program, the firm remains committed to growing through internal programs like Padcev, ...

During Pfizer's right-sizing push after the COVID-19 pandemic, the company's multibillion-dollar cost-cutting campaign has ...

(PFE) is running a Phase 2 trial of ritlecitinib in adults with moderate to severe hidradenitis suppurativa, a chronic skin disease that causes painful lumps. The study, officially titled “A Phase 2, ...